Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy
Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)—and could challenge the current treatment standard (Abstract 6).